April 29, 2025

New Drug Tames Resistant High Blood Pressure

Lorundrostat reduces blood pressure significantly in patients with treatment-resistant hypertension by targeting aldosterone production.

Conexiant

April 28, 2025

Higher Heart Risk Seen in Inflammatory Arthritis With IFG

Prediabetes in inflammatory arthritis patients raised cardiovascular risk by over twofold, researchers reported in a population-based cohort study.

Conexiant

April 28, 2025

Can Lower Blood Pressure Prevent Dementia?

‘Intensive BP reduction is effective in lowering the risk of all-cause dementia,’ a large trial finds

Conexiant

April 28, 2025

Brisk Walking Linked to Reduced Arrhythmia Risk Study

Faster walking pace was associated with a decreased risk of cardiac arrhythmias, researchers wrote in the UK Biobank study.

Conexiant

April 28, 2025

Hormone Therapy Shows Mixed Effects on Heart Biomarkers

In WHI trial, hormone therapy reduced LDL and insulin resistance but raised triglycerides, with strongest lipoprotein(a) reductions seen in Native and Asian women.

Conexiant

April 23, 2025

Sense of Belonging 'Critical' for Workplace Retention

Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.

Conexiant

April 23, 2025

Life's Essential 8 Helps Predict CVD

"Greater cumulative CVH and improvement in CVH during young adulthood, as well as better CVH in middle age, were all independently associated with lower risk for incident CVD in midlife."

Conexiant

April 22, 2025

AHA Framework Maps HF Prevention Strategy

“The growing morbidity, mortality, and health care costs related to heart failure underscore the urgent need to prioritize its primary prevention.”

Conexiant

April 22, 2025

Dual Therapy Lowers Death Risk in Diabetes Study

A large study found that combining GLP-1 receptor agonists with thiazolidinediones significantly reduced death and heart risks in patients with type 2 diabetes.

Conexiant